Brimonidine
Back to search| Scientific Name: | Brimonidine |
| Brand Name: | Alphagan, Combigan, Lumify, Mirvaso, Onreltea, Qoliana, Simbrinza |
| Company Owner: | Allergan inc, Allergan, Akorn inc, Alcon inc, Alcon research ltd, Bausch and lomb pharmaceuticals inc, Sandoz canada inc, Teva parenteral medicines inc, Allergan, Inc |
| Mechanism Of Action | In the eye, alpha-1 adrenoceptors play a role in vasoconstriction, mydriasis, eyelid retraction, and elevation of intraocular pressure (IOP) whereas alpha-2 adrenoceptors are responsible for IOP reduction via a complex Gi-coupled signaling cascade pathway. Activation of alpha-2 receptors leads to inhibition of adenylyl cyclase and reduction of cyclic AMP levels. As a result, there is a decrease in norpinephrine (NE) release at the synaptic junction, NE-induced stimulation of beta-2 adrenoceptors, and production of aqueous humor by the ciliary epithelium. |
| Description of the Drug: | Brimonidine is an alpha-2 adrenergic agonist used to treat glaucoma and ocular hypertension, as well as facial erythema in rosacea. |
| Protein Data Bank: |
Source: DrugBank Online – DrugBank.com. Retrieved 2023-01-23 from https://go.drugbank.com/drugs/DB00484
